Clinical trial · Interventional
Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor
NCT05502458CI-TRIAL-00060355completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the effects of perioperative anesthetic drugs propofol and desflurane on circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA) in the blood of patients with liver cancer, so as to provide scientific reference for clinical anesthesia in the perioperative treatment of tumor
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cells | — | UNRESOLVED | — |
| Desflurane Adverse Reaction | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Propofol Adverse Reaction | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Desflurane | Drug | — | UNRESOLVED |
| Propofol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- propofol
- description
- propofol（50ml,1g）,Intravenous propofol infusion was slowly pushed until loss of consciousness, and anesthesia was maintained at 4-8 mg/kg/h
- interventionNames
- Drug: Propofol
- type
- ACTIVE_COMPARATOR
- label
- desflurane
- description
- In the general anesthesia group with desflurane( 240ml), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane
- interventionNames
- Drug: Desflurane
Primary outcomes (1)
- measure
- The changes of circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA) in peripheral blood of patients with hepatocellular carcinoma after perioperative treatment with propofol and desflurane
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age range: 18 to 75 * ASA: I-III * primary liver cancer (CNLC: Stage I-IIIA) * undergoing elective hepatectomy Exclusion Criteria: * Patients with severe bradycardia (HR \< 55bpm) * patients with severe arrhythmias or cardiac dysfunction (EF \< 35%) * patients with severe respiratory lung disease * patients with severe liver and kidney insufficiency epilepsy * patients with severe hyperlipidemia * patients with a history of malignant hyperthermia * patients with propofol or desflurane allergy * patients with history of preoperative chemoradiotherapy * patients who were on immunosuppressive treatment * patients with chronic opioid therapy declined to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.